Sign In
Buy FEMY
$0.368
-0.0032 (-0.86%)
At Close: Jun 03, 2026
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
09:00am, Wednesday, 13'th May 2026
-- New catheter complements FemVue® and supports streamlined in-office fertility evaluation -- -- New catheter complements FemVue® and supports streamlined in-office fertility evaluation --
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
04:05pm, Friday, 08'th May 2026
-- With fertility rates at historic lows, Femasys advances access to early infertility care through FemaSeed® Complete, enabling OB/GYNs to treat patients within their own practices -- -- With fertil
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
09:00am, Tuesday, 05'th May 2026
-- Integrated sperm preparation and intratubal insemination drive earlier intervention and streamlined, in-office care within routine OB/GYN practice -- ATLANTA, May 05, 2026 (GLOBE NEWSWIRE) -- Femas
Financial Analysis: CRISPR Therapeutics (NASDAQ:CRSP) and Femasys (NASDAQ:FEMY)
01:29am, Friday, 17'th Apr 2026
CRISPR Therapeutics (NASDAQ: CRSP - Get Free Report) and Femasys (NASDAQ: FEMY - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update
04:05pm, Tuesday, 31'st Mar 2026
-- Enrollment underway in FDA-authorized FINALE pivotal trial demonstrating execution toward FemBloc® U.S. approval -- -- Enrollment underway in FDA-authorized FINALE pivotal trial demonstrating exec
Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:26pm, Friday, 27'th Feb 2026
ATLANTA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to w
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination
09:00am, Monday, 23'rd Feb 2026
-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment -- ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedica
Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care
09:00am, Tuesday, 13'th Jan 2026
Partnership enables broader adoption of FemaSeed through a trusted community health provider serving a large, engaged patient population Partnership enables broader adoption of FemaSeed through a trus
Femasys (NASDAQ:FEMY) Stock Price Up 0.1% – What’s Next?
01:38am, Tuesday, 13'th Jan 2026
Femasys Inc. (NASDAQ: FEMY - Get Free Report) shares traded up 0.1% during trading on Monday. The stock traded as high as $0.60 and last traded at $0.5948. 629,160 shares were traded during mid-day tr
Reviewing Femasys (NASDAQ:FEMY) and Response Genetics (OTCMKTS:RGDXQ)
01:32am, Monday, 22'nd Dec 2025
Response Genetics (OTCMKTS:RGDXQ - Get Free Report) and Femasys (NASDAQ: FEMY - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device
09:15am, Thursday, 18'th Dec 2025
-- Innovative single-device solution integrates proven FemVue and FemChec ® technologies to support fallopian tube evaluation and improve workflow efficiency-- ATLANTA, Dec. 18, 2025 (GLOBE NEWSWIRE)
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment
09:15am, Tuesday, 25'th Nov 2025
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ: FEMY), fur
-- Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval -- -- $12 million senior secured conve
Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo
09:00am, Thursday, 16'th Oct 2025
SAN ANTONIO, Texas, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-eff
Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®
09:00am, Thursday, 11'th Sep 2025
-- Following the Setup Kit, the Insemination Kit completes the sperm preparation portion of FemSperm enabling gynecology call point activation to drive revenue growth -- -- Following the Setup Kit, th
